4-(1,3-dioxolan-2-yl)-6-methoxyhexanal | 188125-30-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氧戊环
• 英文名称: 4-(1,3-dioxolan-2-yl)-6-methoxyhexanal
• CAS: 188125-30-6
• 化学式: C₁₀H₁₈O₄
• 分子量: 202.251
• InChiKey: KOWCVKFOFUQVSN-UHFFFAOYSA-N

物化性质

• 沸点：
  286.7±25.0 °C(Predicted)
• 密度：
  1.049±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  14
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 3-benzyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole-5-carboxylate 、 4-(1,3-dioxolan-2-yl)-6-methoxyhexanal 在 4 A molecular sieve 作用下， 以 甲苯 为溶剂， 反应 12.0h， 以82%的产率得到methyl (3aSR,4RS,11bSR)-3-benzyl-2,3,3a,4,5,7-hexahydro-4-[(2-ξ-(1,3-dioxolan-2-yl)-4-methoxy)-1-butyl]-1H-pyrrolo[2,3-d]carbazole-6-carboxylate
  参考文献：
  名称：

  Total syntheses of racemic albifloranine and its anti-addictive congeners, including 18-methoxycoronaridine

  摘要：

  Condensation of methyl 3-benzyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole-5-carboxylate (12) with 4-(1,3-dioxolan-2-yl)-6-benzylaxyhexanal (11a) provided the tetracyclic intermediates methyl (3aSR,4RS,11bRS)-3-benzyl-2,3,3a,4,5,7-hexahydro-4-[2-zeta-(1,3-dioxalan-2-yl)-4-benzyloxy)-1-butyl]-1H-pyrrolo[2,3-d]carbazole-6-carboxylates (14a,15a), which were further elaborated to afford racemic albifloranine (3). The first total synthesis of albifloranine was completed in 13 steps, with an overall 7% yield. Ester and ether derivatives of albifloranine were synthesized for evaluation as anti-addictive agents. Among these, 18-methoxycoronaridine (20b) stands out as a nontoxic agent that significantly reduces demand for morphine, cocaine, nicotine and alcohol in rats. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(99)00513-x
• 作为产物：
  描述：

  烯丙基丙二酸二乙酯 在 对甲苯磺酸 lithium aluminium tetrahydride 、 草酰氯 、 dimethyl sulfide borane 、 sodium ethanolate 、 二甲基亚砜 、 三乙胺 、 lithium chloride 作用下， 以 乙醚 、 乙醇 、 二氯甲烷 、 水 、 二甲基亚砜 、 N,N-二甲基甲酰胺 、 苯 为溶剂， 反应 29.0h， 生成 4-(1,3-dioxolan-2-yl)-6-methoxyhexanal
  参考文献：
  名称：

  Total syntheses of racemic albifloranine and its anti-addictive congeners, including 18-methoxycoronaridine

  摘要：

  Condensation of methyl 3-benzyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole-5-carboxylate (12) with 4-(1,3-dioxolan-2-yl)-6-benzylaxyhexanal (11a) provided the tetracyclic intermediates methyl (3aSR,4RS,11bRS)-3-benzyl-2,3,3a,4,5,7-hexahydro-4-[2-zeta-(1,3-dioxalan-2-yl)-4-benzyloxy)-1-butyl]-1H-pyrrolo[2,3-d]carbazole-6-carboxylates (14a,15a), which were further elaborated to afford racemic albifloranine (3). The first total synthesis of albifloranine was completed in 13 steps, with an overall 7% yield. Ester and ether derivatives of albifloranine were synthesized for evaluation as anti-addictive agents. Among these, 18-methoxycoronaridine (20b) stands out as a nontoxic agent that significantly reduces demand for morphine, cocaine, nicotine and alcohol in rats. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(99)00513-x

文献信息

• NOVEL PHARMACEUTICAL INTERMEDIATES AND METHODS FOR PREPARING THE SAME
  申请人：Boulanger William Allen

  公开号：US20130178618A1

  公开（公告）日：2013-07-11

  A pharmaceutical intermediate including a first indole moiety which is associated with an optionally carboxylated hexahydroazepino moiety, an optionally carboxylated azonane moiety, or a second, optionally carboxylated indole moiety, having an alkyl, allyl, phenylallyl, cinnamyl, alkenyl, and/or alkyl-alkenyl substituent pendant from a nitrogen atom of the same.

  一种药用中间体，包括与可选择地羧化的六氢吲哚基团、可选择地羧化的氮杂环庚烷基团或第二个、可选择地羧化的吲哚基团相关联的第一吲哚基团，其中从同一氮原子悬挂有烷基、烯丙基、苯基丙烯基、肉桂基、烯基和/或烷基-烯基取代基。
• Efficient Preparation of the 18-Methoxycoronaridine Side-Chain Precursor
  作者：R. Herr、Matthew Rainka、Matthew Dowling、Chi-Hsin King、Harold Meckler

  DOI：10.1055/s-2006-942489

  日期：2006.8

  An efficient synthesis of the side-chain precursor crucial to the preparation of 18-methoxycoronaridine (18-MC) has been developed. This procedure represents an improvement upon the original synthesis, in which regioisomers were separated by chromatography to provide the requisite precursor. Incorporation of the protected primary alcohol moiety in the early stages of the synthesis provides the requisite regioisomer unambiguously and obviates the need for chromatography at any point.

  对制备 18-甲氧基可可碱（18-MC）至关重要的侧链前体的高效合成方法已经开发出来。这种合成方法改进了原来的合成方法，即通过色谱法分离regioisomers来提供所需的前体。在合成的早期阶段加入受保护的伯醇分子，可以明确地提供所需的区域异构体，而无需在任何阶段进行色谱分析。
• [EN] IBOGAMINE CONGENERS<br/>[FR] CONGENERES D'IBOGAMINE
  申请人：ALBANY MEDICAL COLLEGE

  公开号：WO1997005869A1

  公开（公告）日：1997-02-20

  (EN) The present invention is directed to compounds having formula (1), wherein n is from 0 to 8; R1 is CH2OH, CH(OH)R5, CH2OR5, CO2R5, C(O)NH2, C(O)NHR5, C(O)NR5R6, C(O)NHNH2, C(O)NHNHR5, C(O)NHNR5R6, C(O)NR5NH2, C(O)NR5NHR6, C(O)NR5NR6R7, C(O)NHNH(C(O)R5), C(O)NHNR5(C(O)R6), C(O)NR5NH(C(O)R6), C(O)NR5NR6(C(O)R7), CN, or C(O)R5; R2 is H, unsubstituted or substituted alkyl, YH, YR8, YC(O)R8, C(O)YR8, C(O)NH2, C(O)NHR8, C(O)NR8R9, NH2, NHR8, NR8R9, NHC(O)R8, or NR8C(O)R9; R3 and R4 are the same or different and are selected from the group consisting of H, halogens, unsubstituted or substituted alkyl, OH, OR10, NH2, NHR10, NR10R11, NHC(O)R10, or NR10C(O)R11; R5, R6, R7, R8, R9, R10, and R11 are the same or different and are selected from the group consisting of unsubstituted alkyl and substituted alkyl; R12 is selected from the group consisting of H, unsubstituted alkyl, and substituted alkyl; and Y is O or S; provided that when n is O, R2 is selected from the group consisting of H, substituted alkyl, and unsubstituted alkyl; and pharmaceutically acceptable salts thereof. The compounds are useful in the treatment of subjects addicted to opiates and stimulants and have reduced side effects relative to other ibogamine congeners.(FR) L'invention concerne des composés représentés par la formule, dans laquelle, n vaut 0 à 8; R1 représente CH2OH, CH(OH)R5, CH2OR5, CO2R5, C(O)NH2, C(O)NHR5, C(O)NR5R6, C(O)NHNH2, C(O)NHNHR5, C(O)NHNR5R6, C(O)NR5NH2, C(O)NR5NHR6, C(O)NR5NR6R7, C(O)NHNH(C(O)R5), C(O)NHNR5(C(O)R6), C(O)NR5NH(C(O)R6) C(O)NR5NR6(C(O)R7), CN ou C(O)R5; R2 représente H, alkyle substitué ou non, YH, YR8, YC(O)R8, C(O)YR8, C(O)NH2, C(O)NHR8, C(O)NR8R9, NH2, NHR8, NR8R9, NHC(O)R8 ou NR8C(O)R9; R3 et R4 sont semblables ou différents et sont sélectionnés dans le groupe constitué par H, halogènes, alkyle substitué ou non, OH, OR10, NH2, NHR10, NR10R11, NHC(O)R10 ou NR10C(O)R11; R5, R6; R7, R8, R9, R10 et R11 sont semblables ou différents et sont sélectionnés dans le groupe constitué par alkyle non substitué et alkyle substitué; R12 est sélectionné dans le groupe constitué par H, alkyle non substitué et alkyle substitué; Y représente O ou S; à savoir que, quand n vaut 0, R2 est sélectionné dans le groupe constitué par H, alkyle substitué et alkyle non substitué; ainsi que leurs sels acceptables sur le plan pharmaceutique. Ces composés sont utiles pour traiter des sujets dépendants des opiacés et des stimulants et présentent des effets secondaires limités par rapport à d'autres congénères d'ibogamine.

  本发明涉及具有式（1）的化合物，其中n为0至8; R1为CH2OH，CH（OH）R5，CH2OR5，CO2R5，C（O）NH2，C（O）NHR5，C（O）NR5R6，C（O）NHNH2，C（O）NHNHR5，C（O）NHNR5R6，C（O）NR5NH2，C（O）NR5NHR6，C（O）NR5NR6R7，C（O）NHNH（C（O）R5），C（O）NHNR5（C（O）R6），C（O）NR5NH（C（O）R6），C（O）NR5NR6（C（O）R7），CN或C（O）R5; R2为H，未取代或取代的烷基，YH，YR8，YC（O）R8，C（O）YR8，C（O）NH2，C（O）NHR8，C（O）NR8R9，NH2，NHR8，NR8R9，NHC（O）R8或NR8C（O）R9; R3和R4相同或不同，选择自H，卤素，未取代或取代的烷基，OH，OR10，NH2，NHR10，NR10R11，NHC（O）R10或NR10C（O）R11的群; R5，R6，R7，R8，R9，R10和R11相同或不同，选择自未取代的烷基和取代的烷基的群; R12选择自H，未取代的烷基和取代的烷基的群; Y为O或S; 假设当n为O时，R2选择自H，取代的烷基和未取代的烷基的群; 以及其在药学上可接受的盐。这些化合物对治疗对阿片类和兴奋剂上瘾的受试者有用，并且相对于其他伊博加曼同系物具有较少的副作用。
• Ibogamine congeners
  申请人：Albany Medical College

  公开号：US06211360B1

  公开（公告）日：2001-04-03

  The present invention is directed to compounds having formula (1), wherein n is from 0 to 8; R1 is CH2OH, CH(OH)R5, CH2OR5, CO2R5, C(O)NH2, C(I)NHR5, C(O)NR5R6, C(O)NHNH2, C(O)NHNHR5, C(O)NHNR5R6, C(O)NR5NH2, C(O)NR5NHR6, C(O)NR5NR6R7, C(O)NHNH(C(O)R5), C(O)NHNR5(C(O)R6) C(O)NR5NH(C(O)R6), C(O)NR5NR6(C(O)R7), CN, or C(O)R5; R2 is H, unsubstituted or substituted alkyl, YH, YR8, YC(O)R8, C(O)YR8, C(O)NH2, C(O)NHR8, C(O)NR8R9, NH2, NHR8, NR8R9, NHC(O)R8, or NR8C(O)R9; R3 and R4 are the same or different and are selected from the group consisting of H, halogens, unsubstituted or substituted alkyl, OH, OR10, NH2, NHR10, NR10R11, NHC(O)R10, or NR10C(O)R11; R5, R6, R7, R8, R9, R10, and R11 are the same or different and are selected from the group consisting of unsubstituted alkyl and substituted alkyl and substituted alkyl; R12 is selected from the group consisting of J, unsubstituted alkyl, and substituted alkyl; and Y is O or S; provided that when n is O, R2 is selected from the group consisting of H, substituted alkyl, and unsubstituted alkyl; and pharmaceutically acceptable salts thereof. The compounds are useful in the treatment of subjects addicted to opiates and stimulants and have reduced side effects relative to other ibogamine congeners.

  本发明涉及具有公式（1）的化合物，其中n为0到8；R1为CH2OH，CH（OH）R5，CH2OR5，CO2R5，C（O）NH2，C（I）NHR5，C（O）NR5R6，C（O）NHNH2，C（O）NHNHR5，C（O）NHNR5R6，C（O）NR5NH2，C（O）NR5NHR6，C（O）NR5NR6R7，C（O）NHNH（C（O）R5），C（O）NHNR5（C（O）R6），C（O）NR5NH（C（O）R6），C（O）NR5NR6（C（O）R7），CN或C（O）R5；R2为H，未取代或取代的烷基，YH，YR8，YC（O）R8，C（O）YR8，C（O）NH2，C（O）NHR8，C（O）NR8R9，NH2，NHR8，NR8R9，NHC（O）R8或NR8C（O）R9；R3和R4相同或不同，并选择自H，卤素，未取代或取代的烷基，OH，OR10，NH2，NHR10，NR10R11，NHC（O）R10或NR10C（O）R11的群组中；R5，R6，R7，R8，R9，R10和R11相同或不同，并选择自未取代的烷基和取代的烷基和取代的烷基的群组中；R12选择自J，未取代的烷基和取代的烷基的群组中；Y为O或S；前提是当n为0时，R2选择自H，取代烷基和未取代烷基的群组中；以及其药学上可接受的盐。这些化合物在治疗对阿片类和兴奋剂上瘾的受试者方面是有用的，并且相对于其他伊博加明同系物具有减少的副作用。
• Novel Pharmaceutical Intermediates and Methods for Preparing the Same
  申请人：Boulanger William Allen

  公开号：US20140213782A1

  公开（公告）日：2014-07-31

  A pharmaceutical intermediate including a first indole moiety which is associated with an optionally carboxylated hexahydroazepino moiety, an optionally carboxylated azonane moiety, or a second, optionally carboxylated indole moiety, having an alkyl, allyl, phenylallyl, cinnamyl, alkenyl, and/or alkyl-alkenyl substituent pendant from a nitrogen atom of the same.

  一种药用中间体，包括第一吲哚基团，该基团与可选的羧化的六氢-氮杂环基团、可选的羧化的氮杂烷基团或第二个可选的羧化的吲哚基团相关联，并且在同一氮原子上具有烷基、丙烯基、苯基丙烯基、肉桂基、烯基和/或烷基-烯基取代基。